Vertex’s Exa-Cel Off-Target Analyses Set Early Bar For Other Genome Editing Products
US FDA draft guidance does not specify the number of donor samples to test in nonclinical studies or the process for detecting genetic variants potentially susceptible to off-target effects. An advisory committee found adequate Vertex's analyses, which the sponsor called ‘the most comprehensive evaluation of off-target potential performed to date.’
You may also be interested in...
Julie Tierney will become CBER’s deputy director for strategy, policy and legislation, a newly created position.
CBER’s director says manufacturing and regulatory issues need to be resolved to ensure the gene therapy sector thrives.
US FDA advisory committee members questioned how potential off-target effects with Vertex’s gene therapy for sickle cell disease should be conveyed to patients and families, and whether labeling should say anything about these theoretical risks.